Enanta Pharmaceuticals (ENTA) Set to Announce Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) will likely be releasing its Q4 2026 resultson Monday, November 16th. Analysts expect Enanta Pharmaceuticals to post earnings of ($0.7240) per share and revenue of $14.62 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2026 earnings results page for the latest details on the call scheduled for Monday, November 16, 2026 at 4:00 PM ET.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. The firm had revenue of $14.36 million for the quarter, compared to analyst estimates of $16.76 million. On average, analysts expect Enanta Pharmaceuticals to post ($2.36) EPS for the current fiscal year and ($2.50) EPS for the next fiscal year.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $11.00 on Monday. Enanta Pharmaceuticals has a 52 week low of $10.05 and a 52 week high of $17.15. The firm has a 50 day moving average of $12.19 and a two-hundred day moving average of $13.12. The stock has a market capitalization of $320.32 million, a PE ratio of -4.56 and a beta of 0.75.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, October 11th. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday, September 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Thursday, October 15th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company’s research has primarily centered on treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), and other serious infectious diseases.

Enanta’s most notable commercial contribution is its discovery of glecaprevir, an active component of the hepatitis C treatment Mavyret, also marketed as Maviret outside the United States.